| How to Face with Minimally Invasive Abdominal Surgery During Covid-19 Outbreak? Surgical and Anesthesiological Concerns | Mirko BARONE,Marco PRİOLETTA,Luigi GUETTİ,Sonia CAPONE,Larissa Pereira GHAMMACHİ,Massima IPPOLİTİ,Elena CARLUCCİO,Massimo CİERİ,Alessandro MAROLLA,Giuseppe CİPOLLONE,Liberato ACETO,Ivan DELL'ATTİ,Carmine Lanci LANCİ,Salvatore Maurizio MAGGİORE,Felice MUCİLLİ | 181–184 |
| The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2 | Rohan R. NARKHEDE,Rameshwar S. CHEKE,Jaya P AMBHORE,Sachin D.SHİNDE | 185–195 |
| IN Silico Approach of Some Selected Honey Constituents as SARS-CoV-2 Main Protease (COVID-19) Inhibitors | Heba E. HASHEM | 196–200 |
| Epitope-Based Vaccine Design against Novel Coronavirus SARS-CoV-2 Envelope Protein | Hanuman Singh DAGUR,Saurabh Singh DHAKAR,Apporva GUPTA | 201–208 |
| Immunotherapy in Geriatric Patients With Advanced Cancer | Birol YILDIZ,Ramazan ACAR | 209–214 |
| The Relationship Between Primary Tumor Localization and Driver Mutation in Lung Cancer | Cengiz KARAÇİN,Tülay EREN,Gökşen İnanç İMAMOĞLU,Sema TÜRKER,Fevzi Çoşkun SÖKMEN,Mustafa ALTINBAŞ | 215–218 |
| Hydroxychloroquine as Potent Inhibitor of COVID -19 Main Protease: Grid Based Docking Approach | Jitender Kumar MALİK,Himesh SONİ,Sarvesh SHARMA,Satish SARANKAR | 219–226 |
| Health-Related Quality of life of Patients Surgically Treated for benign Oral and Maxillofacial Tumours and Tumour-like lesions at Muhimbili National Hospital, Tanzania | Nalumino SAYELA,Sira Stanslaus OWİBİNGİRE,Boniphace KALYANYAMA,Karpal Singh SOHAL | 227–233 |
| Bioinformatics Approach for COVID-19 (Coronavirus) Disease Prevention Treatment and Drug Validation | Shruti MİSHRA,Prashant Ankur JAİN,Shmmon Ahmad,Shivam MİSHRA | 234–238 |
| Neck Metastasis of Glioblastoma: Rare Case | Andina WİRATHMAWATİ,Dessika RAHMAWATİ,Eko Arisetijono MARHAENDRAPUTRO,Shahdevi Nandar KURNİAWAN,Yuyun YUENİWATİ | 239–245 |
| Pneumocystis Jiroveci Mimicking COVID-19 Pneumonia in a Patient who is Receiving Ipilimumab and Nivolumab Combination Therapy: A Case Report |